Features and therapeutic potential of T-cell receptors in high-grade glioma
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 12
- DOI:
- 10.1097/CM9.0000000000000282
- Key Word:
- Glioma;T-cell receptor;Immunotherapy;Survival;Therapeutics
Abstract： Background:Previous studies have shown that endogenous T cells play an important role in the prolonged survival time of high-grade glioma (HGG) patients.Our objectives were to investigate the features of T-cell receptor (TCR) repertoires in HGG patients and to elucidate any potential therapeutic value.Methods:During November 2011 and December 2018,tumor tissues and blood samples of 35 patients with HGG who underwent surgery at Beijing Tiantan Hospital or Beijing Shijitan Hospital were selected after surgery.After isolating DNA from samples,multiple rounds of PCR were performed to establish a DNA immune repertoire (IR).Then,the sequences and frequencies of the complementarity-determining 3 (CDR3) region in TCR beta chain (TRB) were identified by high-throughput sequencing and IR analysis.A survival follow-up was conducted monthly thereafter until December 2018.Finally,the t test and Mann-Whitney test were used to compare statistical differences between two sets of data.Results:The Shannon diversity index (SHDI) of TRB sequences of HGG patients was significantly lower than that of healthy individuals (7.34 vs.8.45,P =0.001).The SHDI of TRB sequences of glioblastoma (GBM) patients with more than 16 months survival time was much higher than that of GBM patients with shorter survival times in both tumor tissues (3.48 ± 0.31 vs.6.21 ± 0.33,t =-5.49,P =0.002) and blood cells (6.02 ± 0.66 vs.7.44 ± 0.32,t =-2.20,P =0.036).In addition,patients achieved a distinctly higher proportion compared to that of healthy individuals in the proportion of TRBV9 and TRBV5 functional regions (9.83 ％ vs.6.83％,P =0.001).Surgical tissue from patients who survived more than 16 months yielded a much higher proportion of TRBV4 and TRBV9 regions (7.14％ vs.3.28％,t =3.18,P =0.019).In surgical tissues from two GBM patients who survived for longer than 46 months,we found a potentially therapeutic TCR sequence.Conclusions:HGG patients have less species diversity of TCR repertoires compared with that of healthy individuals.TRBV9 regions in TCRs may be protective factors for long-term survival of GBM patients.
- [1]M, Fehlings,Y, Simoni,H L, Penny,etc.Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.[J].2017,8(1).
- [2]Antonio Simone Laganà,Salvatore Giovanni Vitale,Francesca Maria Salmeri,etc.Unus pro omnibus, omnes pro uno: A novel, evidence-based, unifying theory for the pathogenesis of endometriosis[J].2017,103.
- [3]Robins, Harlan.Immunosequencing: applications of immune repertoire deep sequencing[J].2013,25(5).
- [4]Birnbaum, M. E.,Mendoza, J. L.,Sethi, D. K.,etc.Deconstructing the Peptide-MHC Specificity of T Cell Recognition[J].2014,157(5).
- [5]Maude,S.L.,Barrett,D.,Teachey,D.T.,etc.Managing cytokine release syndrome associated with novel T cell-engaging therapies[J].2014,20(2).
- [6]Murugaesu, Nirupa,Wilson, Gareth A.,Birkbak, Nicolai J.,etc.Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy[J].2015,5(8).
- [7]Qingzhu,Jia,Wei,Wu,Yuqi,Wang,etc.Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer.[J].2018,9(1).
- [8]Bonini, Chiara,Mondino, Anna.Adoptive T-cell therapy for cancer: The era of engineered T cells[J].2015,45(9).
- [9]Lehman, Jonathan M.,Gwin, Mary E.,Massion, Pierre P..Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope[J].2017,19(9/10).
- [10].Invariant NKT Cells: Regulation and Function during Viral Infection.[J].2012,8(8).
- [11]Dudley ME,Johnson LA,Morgan RA.Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.[J].2009,114(3).
- [12]Campregher PV,Srivastava SK,Robins HS.Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.[J].2009,114(19).
- [13]Marco L, Davila,Isabelle, Riviere,Xiuyan, Wang,etc.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.[J].2014,6.
- [14].Advances in Cancer Immunotherapy in Solid Tumors.[J].2016,(12).
- [15]Vetvicka, Vaclav,Lagana, Antonio Simone,Salmeri, Francesca Maria,etc.Regulation of apoptotic pathways during endometriosis: from the molecular basis to the future perspectives[J].2016,294(5).
- [16]Pakawat,Chongsathidkiet,Christina,Jackson,Shohei,Koyama,etc.Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.[J].2018.
- [17]Hinrichs, Christian S..Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy[J].2016,22(7).
- [18]John,Lynes,Victoria,Sanchez,Gifty,Dominah,etc.Current Options and Future Directions in Immune Therapy for Glioblastoma.[J].2018,8.
- [19]Liu, X. Shirley,Mardis, Elaine R..Applications of Immunogenomics to Cancer[J].2017,168(4).
- [20]Nabil Ahmed,Vita Brawley,Meenakshi Hegde,etc.Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.[J].2015,3(O11).
- [21]Yarchoan, Mark,Johnson, Burles A., III,Lutz, Eric R.,etc.Targeting neoantigens to augment antitumour immunity[J].2017,17(4).
- [22]Bolotin, Dmitriy A.,Poslavsky, Stanislav,Mitrophanov, Igor,etc.MiXCR: software for comprehensive adaptive immunity profiling[J].2015,12(5).
- [23]Bendle GM,Schumacher TN,Linnemann C.T-cell receptor gene therapy: critical parameters for clinical success.[J].2011,131(9).
- [24]Sahin, Ugur,Derhovanessian, Evelyna,Miller, Matthias,etc.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer[J].2017,547(Jul.13 TN.7662).
- [25]Shyamala, Maheswaran,Lecia V, Sequist,Sunitha, Nagrath,etc.Detection of mutations in EGFR in circulating lung-cancer cells.[J].2008,359.
- [26]Moran AE,Holzapfel KL,Xing Y,etc.T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse.[J].2011,208(6).
- [27]Patrick Y. Wen,Santosh Kesari.Malignant Gliomas in Adults[J].2008,359(5).
- [28]Quinn T, Ostrom,Haley, Gittleman,Jordonna, Fulop,etc.CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.[J].2015,17.
- [29]thor Straten P,Brocker EB,Seremet T,etc.Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.[J].1996,98(2).
- [30]Brown, Christine E.,Alizadeh, Darya,Starr, Renate,etc.Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy[J].2016,375(26).
- [31]Greene, Lisa M.,Nathwani, Seema M.,Zisterer, Daniela M..Inhibition of -secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5[J].2016,12(4).
- [32]Yoshida, Kengo,Cologne, John B.,Cordova, Kismet,etc.Aging-related changes in human T-cell repertoire over 20 years delineated by deep sequencing of peripheral T-cell receptors[J].2017,96.
- [33]Chinot,O.L.,Wick,W.,Mason,W.,etc.Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma[J].2014,370(8).
- [34]Alvin J X, Lee,David, Endesfelder,Andrew J, Rowan,etc.Chromosomal instability confers intrinsic multidrug resistance.[J].2011,71.
- [35]Gerlinger M,Swanton C.How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.[J].2010,103(8).